The emerging safety profile of JAK inhibitors in rheumatic disease

KL Winthrop - Nature Reviews Rheumatology, 2017 - nature.com
Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of
rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …

Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity

J Bustamante, S Boisson-Dupuis, L Abel… - Seminars in …, 2014 - Elsevier
Mendelian susceptibility to mycobacterial disease (MSMD) is a rare condition characterized
by predisposition to clinical disease caused by weakly virulent mycobacteria, such as BCG …

STAT1 and its crucial role in the control of viral infections

M Tolomeo, A Cavalli, A Cascio - International Journal of Molecular …, 2022 - mdpi.com
The signal transducer and activator of transcription (STAT) 1 protein plays a key role in the
immune response against viruses and other pathogens by transducing, in the nucleus, the …

JAKs and STATs in immunity, immunodeficiency, and cancer

JJ O'Shea, SM Holland, LM Staudt - New England Journal of …, 2013 - Mass Medical Soc
JAKs and STATs in Immunity, Immunodeficiency, and Cancer | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Mendelian susceptibility to mycobacterial disease: recent discoveries

J Bustamante - Human genetics, 2020 - Springer
Mendelian susceptibility to mycobacterial disease (MSMD) is caused by inborn errors of IFN-
γ immunity. Affected patients are highly and selectively susceptible to weakly virulent …

Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome

AY Kreins, MJ Ciancanelli, S Okada, XF Kong… - Journal of Experimental …, 2015 - rupress.org
Autosomal recessive, complete TYK2 deficiency was previously described in a patient (P1)
with intracellular bacterial and viral infections and features of hyper-IgE syndrome (HIES) …

Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy

S Okada, T Asano, K Moriya, S Boisson-Dupuis… - Journal of clinical …, 2020 - Springer
Heterozygous gain-of-function (GOF) mutations in STAT1 in patients with chronic
mucocutaneous candidiasis (CMC) and hypothyroidism were discovered in 2011. CMC is …

Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

L Liu, S Okada, XF Kong, AY Kreins… - Journal of Experimental …, 2011 - rupress.org
Chronic mucocutaneous candidiasis disease (CMCD) may be caused by autosomal
dominant (AD) IL-17F deficiency or autosomal recessive (AR) IL-17RA deficiency. Here …

Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

CJA Duncan, MK Skouboe, S Howarth… - Journal of Experimental …, 2022 - rupress.org
Type I interferons (IFN-I) play a critical role in human antiviral immunity, as demonstrated by
the exceptionally rare deleterious variants of IFNAR1 or IFNAR2. We investigated five …

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

A Puel, R Döffinger, A Natividad, M Chrabieh… - Journal of Experimental …, 2010 - rupress.org
Most patients with autoimmune polyendocrine syndrome type I (APS-I) display chronic
mucocutaneous candidiasis (CMC). We hypothesized that this CMC might result from …